Advances in Y-90 radioembolization for the treatment of hepatocellular carcinoma (2024)

1. JemalA, WardEM, JohnsonCJ, et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst 2017:109.

2. SiegelR, MaJ, ZouZ, JemalA. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.

3. KulikL. Criteria for liver transplantation in hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2015;6:100-2.

4. VillanuevaA. Hepatocellular carcinoma. N Engl J Med 2019;380:1450-62.

5. LlovetJM, BrúC, BruixJ. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-38.

6. LlovetJM, Di BisceglieAM, BruixJ, et al. Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.

7. BensonAB, D'AngelicaMI, AbbottDE, et al. Hepatobiliary cancers, version 2.2021, NCCN Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2021;19:541-65.

8. SalemR, GordonAC, MouliS, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2016;151:1155-63.e2.

9. LewandowskiRJ, GabrA, AbouchalehN, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology 2018;287:1050-8.

10. PadiaSA, JohnsonGE, HortonKJ, et al. Segmental yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective, propensity score-matched study. J Vasc Interv Radiol 2017;28:777-85.e1.

11. RiazA, GatesVL, AtassiB, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys 2011;79:163-71.

12. MarreroJA, KulikLM, SirlinCB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Hepatology 2018;68:723-50.

13. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu., European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.

14. LlovetJM, RealMI, MontañaX, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9.

15. LoCM, NganH, TsoWK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71.

16. SangroB, CarpaneseL, CianniR, et al. European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011;54:868-78.

17. KalliniJR, GabrA, SalemR, LewandowskiRJ. Transarterial radioembolization with yttrium-90 for the treatment of hepatocellular carcinoma. Adv Ther 2016;33:699-714.

18. TongAK, KaoYH, TooCW, ChinKF, NgDC, ChowPK. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol 2016;89:20150943.

20. KennedyA, NagS, SalemR, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007;68:13-23.

21. SalemR, PadiaSA, LamM, et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging 2019;46:1695-704.

22. ParkW, LimDH, PaikSW, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2005;61:1143-50.

23. KimTH, KimDY, ParkJW, et al. Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2007;67:225-31.

24. SonSH, JangHS, JoIY, et al. Significance of an increase in the Child-Pugh score after radiotherapy in patients with unresectable hepatocellular carcinoma. Radiat Oncol 2014;9:101.

25. VoucheM, HabibA, WardTJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology 2014;60:192-201.

26. GarinE, TselikasL, GuiuB, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021;6:17-29.

27. KappadathSC, MikellJ, BalagopalA, BaladandayuthapaniV, KasebA, MahvashA. Hepatocellular carcinoma tumor dose response after 90Y-radioembolization with glass microspheres using 90Y-SPECT/CT-based voxel dosimetry. Int J Radiat Oncol Biol Phys 2018;102:451-61.

28. SongYS, PaengJC, KimHC, et al. PET/CT-based dosimetry in 90Y-microsphere selective internal radiation therapy: single cohort comparison with pretreatment planning on (99m)Tc-MAA imaging and correlation with treatment efficacy. Medicine (Baltimore) 2015;94:e945.

29. ChanKT, AlessioAM, JohnsonGE, et al. Prospective trial using internal pair-production positron emission tomography to establish the yttrium-90 radioembolization dose required for response of hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2018;101:358-65.

30. GabrA, RiazA, JohnsonGE, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging 2021;48:580-3.

31. Gil-AlzugarayB, ChopiteaA, IñarrairaeguiM, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 2013;57:1078-87.

32. RiazA, LewandowskiRJ, KulikLM, et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 2009;20:1121-30; quiz 1131.

33. SangroB, Martínez-UrbistondoD, BesterL, et al. Prevention and treatment of complications of selective internal radiation therapy: expert guidance and systematic review. Hepatology 2017;66:969-82.

34. De la Garza-RamosC, OverfieldCJ, MontazeriSA, et al. Biochemical safety of ablative yttrium-90 radioembolization for hepatocellular carcinoma as a function of percent liver treated. J Hepatocell Carcinoma 2021;8:861-70.

35. BiedermanDM, TitanoJJ, BishayVL, et al. Radiation segmentectomy versus TACE combined with microwave ablation for unresectable solitary hepatocellular carcinoma up to 3 cm: a propensity score matching study. Radiology 2017;283:895-905.

36. SalemR, JohnsonGE, KimE, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology 2021;74:2342-52.

37. ArndtL, VillalobosA, WagstaffW, et al. Evaluation of medium-term efficacy of Y90 radiation segmentectomy vs percutaneous microwave ablation in patients with solitary surgically unresectable < 4 cm hepatocellular carcinoma: a propensity score matched study. Cardiovasc Intervent Radiol 2021;44:401-13.

38. ToskichB, VidalLL, OlsonMT, et al. Pathologic response of hepatocellular carcinoma treated with yttrium-90 glass microsphere radiation segmentectomy prior to liver transplantation: a validation study. J Vasc Interv Radiol 2021;32:518-26.e1.

39. LuDS, RamanSS, LimanondP, et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol 2003;14:1267-74.

40. LamVW, NgKK, ChokKS, et al. Incomplete ablation after radiofrequency ablation of hepatocellular carcinoma: analysis of risk factors and prognostic factors. Ann Surg Oncol 2008;15:782-90.

41. PadiaSA, KwanSW, RoudsariB, MonskyWL, CovelerA, HarrisWP. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol 2014;25:1067-73.

42. SalemR, GilbertsenM, ButtZ, et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 2013;11:1358-65.e1.

43. SalemR, LewandowskiRJ, KulikL, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140:497-507.e2.

44. Casadei Gardini A, Tamburini E, Iñarrairaegui M, Frassineti GL, Sangro B. Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. Onco Targets Ther 2018;11:7315-21.

45. SalemR, GabrA, RiazA, et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology 2018;68:1429-40.

46. GarinE, RollandY, EdelineJ, et al. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. J Nucl Med 2015;56:339-46.

47. GarinE, RollandY, PrachtM, et al. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microsphere radioembolization. Liver Int 2017;37:101-10.

48. VilgrainV, PereiraH, AssenatE, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017;18:1624-36.

49. ChowPKH, GandhiM, TanSB, et al. Asia-Pacific Hepatocellular Carcinoma Trials Group. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol 2018;36:1913-21.

50. YaoFY, BassNM, NikolaiB, et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003;9:684-92.

51. LlovetJM, BustamanteJ, CastellsA, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:62-7.

52. HalazunKJ, PatzerRE, RanaAA, et al. Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology 2014;60:1957-62.

53. HeimbachJK, KulikLM, FinnRS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358-80.

54. BiedermanDM, TitanoJJ, KorffRA, et al. Radiation segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma. J Vasc Interv Radiol 2018;29:30-7.e2.

55. TohmeS, SukatoD, ChenHW, et al. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience. J Vasc Interv Radiol 2013;24:1632-8.

56. EttorreGM, Levi SandriGB, LaurenziA, et al. Yttrium-90 radioembolization for hepatocellular carcinoma prior to liver transplantation. World J Surg 2017;41:241-9.

57. GabrA, AbouchalehN, AliR, et al. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. Eur J Radiol 2017;93:100-6.

58. GabrA, KulikL, MouliS, et al. Liver transplantation following yttrium-90 radioembolization: 15-year experience in 207-patient cohort. Hepatology 2021;73:998-1010.

59. AgopianVG, MorshediMM, McWilliamsJ, et al. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients. Ann Surg 2015;262:536-45; discussion 543-5.

60. Gordon-WeeksAN, SnaithA, PetrinicT, FriendPJ, BurlsA, SilvaMA. Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria. Br J Surg 2011;98:1201-8.

61. ParikhND, WaljeeAK, SingalAG. Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transpl 2015;21:1142-52.

62. LewandowskiRJ, KulikLM, RiazA, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009;9:1920-8.

63. JakobsTF, SaleemS, AtassiB, et al. Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres. Dig Dis Sci 2008;53:2556-63.

64. KubotaK, MakuuchiM, KusakaK, et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology 1997;26:1176-81.

65. VoucheM, LewandowskiRJ, AtassiR, et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol 2013;59:1029-36.

66. GabaRC, LewandowskiRJ, KulikLM, et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol 2009;16:1587-96.

67. van LiendenKP, van den EsschertJW, de GraafW, et al. Portal vein embolization before liver resection: a systematic review. Cardiovasc Intervent Radiol 2013;36:25-34.

68. PadiaSA, LewandowskiRJ, JohnsonGE, et al. Society of Interventional Radiology Standards of Practice Committee. Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions. J Vasc Interv Radiol 2017;28:1-15.

69. RiazA, AwaisR, SalemR. Side effects of yttrium-90 radioembolization. Front Oncol 2014;4:198.

70. SangroB, Gil-AlzugarayB, RodriguezJ, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 2008;112:1538-46.

71. KennedyAS, McNeillieP, DezarnWA, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 2009;74:1494-500.

72. CollinsJ, SalemR. Hepatic radioembolization complicated by gastrointestinal ulceration. Semin Intervent Radiol 2011;28:240-5.

73. BesterL, MetelingB, PocockN, et al. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol 2012;23:96-105.

74. AyavA, HabibN, JiaoLR. Portal hypertension secondary to 90Yttrium microspheres: an unknown complication. J Clin Oncol 2005;23:8275-6.

75. RickeJ, KlümpenHJ, AmthauerH, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol 2019;71:1164-74.

Advances in Y-90 radioembolization for the treatment of hepatocellular carcinoma (2024)

References

Top Articles
Latest Posts
Recommended Articles
Article information

Author: Manual Maggio

Last Updated:

Views: 6002

Rating: 4.9 / 5 (69 voted)

Reviews: 92% of readers found this page helpful

Author information

Name: Manual Maggio

Birthday: 1998-01-20

Address: 359 Kelvin Stream, Lake Eldonview, MT 33517-1242

Phone: +577037762465

Job: Product Hospitality Supervisor

Hobby: Gardening, Web surfing, Video gaming, Amateur radio, Flag Football, Reading, Table tennis

Introduction: My name is Manual Maggio, I am a thankful, tender, adventurous, delightful, fantastic, proud, graceful person who loves writing and wants to share my knowledge and understanding with you.